MedPage Today – July 16
Elevated levels of the pro-inflammatory protein interleukin-6 may identify patients at increased risk of severe side effects from chimeric antigen receptor T-cell therapy. (Moffitt Cancer Center, Clinical Cancer Research)
Tampa Bay Newswire – July 16
She serves on the Board of Directors of Tampa Electric Company, as well as the H. Lee Moffitt Cancer Center and Research Institute National Board of Advisors.
St. Pete Catalyst – July 16
Dave Summitt, chief information security officer at Moffitt Cancer Center, has been selected for the Federal Communication Commission’s newly formed federal advisory committee, the Hospital Robocall Protection Group.
ASCO Post – July 16
“Identifying which [patients treated with] CAR T-cell therapy may be more susceptible to those severe toxicities before therapy could allow us to better tailor their care to mediate or reduce those adverse reactions,” said corresponding study author Marco Davila, MD, PhD, Associate Member of the Blood and Marrow Transplant and Cellular Immunotherapy Department and Medical Director of Cell Therapies at the H. Lee Moffitt Cancer Center & Research Institute.
Tampa Bay Business Journal - July 16
Dave Summitt, the chief information security officer of Moffitt Cancer Center, has been named to the Hospital Robocall Protection Group, a Federal Communications Commission advisory committee on robocalls, where he will serve as chairperson.
The Oracle – July 16
Fragello said her life was normal prior to December 2019, and she had never experienced a terminal illness or disability. Cancer was hardly ever prevalent in her life until she began volunteering at the H. Lee Moffitt Cancer Center & Research Institute.
OncLive – July 15
Kamran A. Ahmed, MD, an assistant member in the Department of Radiation Oncology and the Department of Immunology at Moffitt Cancer Center, and an assistant professor in the Department of Oncologic Sciences at the University of South Florida, discusses key strategies to manage patients with breast cancer and brain metastases.
OncLive – July 15
In an interview with OncLive, as part of the virtual Institutional Perspectives in Cancer™ on Breast Cancer, Han, a medical oncologist and research director of Breast Oncology at Moffitt Cancer Center, further discussed ongoing clinical trials within the field of HER2-positive breast cancer and the future of personalized treatment for this patient population.
OncLive – July 15
Brian Czerniecki, MD, PhD, chair and senior member, Department of Breast Oncology at Moffitt Cancer Center, discusses treatment options for patients with HER2-positive breast cancer who have brain metastases.
Newswise – July 15
In a new study published in Clinical Cancer Research, Moffitt Cancer Center researchers identify possible factors that could help physicians know if patients are at higher risk for severe adverse events before they receive CAR T therapy. Also posted to ScienceMag and Micro-Biology.
ACA International – July 15
Members include: Chair: Paul D. Summitt, chief information security Officer of the Moffitt Cancer Center
OncLive – July 14
In an interview with OncLive during the Institutional Perspectives in Cancer program, Sam, a hematologist and oncologist and an assistant member in the Department of Individualized Cancer Management/Senior Adult Oncology Program at Moffitt Cancer Center, highlighted strategies to prevent the spread of COVID-19 in geriatric patients with cancer and shared advice on how to overcome unique challenges faced in the care of this population.
Becker’s Hospital Review – July 14
FCC Chairman Ajit Pai designated Tampa, Fla.-based Moffitt Cancer Center Chief Information Security Officer Dave Summitt to chair the Hospital Robocall Protection Group, which will hold its first meeting on July 27.
OncLive – July 14
In an interview with OncLive, Sallman, an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center, discussed the combination of eprenetapopt and azacitidine as a treatment for high-risk patients with TP53-mutant MDS and AML.
Healio – July 14
“The issue with clinical trials is that they often are very highly selective,” Michael D. Jain, MD, PhD, assistant member in the department of blood and marrow transplant and cellular immunotherapy at Moffitt Cancer Center, told Healio.
News Medical – July 14
Moffitt Cancer Center researchers want to learn more about how this type of inhibitor works with the body's immune system to determine if there are ways to predict or mitigate associated adverse effects. Also posted to Newswise and EurekAlert.
Multichannel News – July 14
Commissioner Brendan Carr will represent the FCC and Commissioner Noah Joshua Phillips will represent the Federal Trade Commission. Officers will be Dave Summitt of the Moffitt Cancer Center, chairman; Patrick Halley of USTelecom, vice chair.
OncologyTube – July 14
Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated with neoadjuvant chemotherapy.
Pittsburgh Quarterly – Summer 2020
“We have trained a dozen people who have taken over melanoma programs at places such as UNC-Chapel Hill, Cleveland Clinic, Moffitt Cancer Center and MD Anderson [Cancer Center].”
Healio – July 13
More importantly, we recruited Dr. Quinn, who came to us from Moffitt Cancer Center and had done these studies. The second paper she wrote looked at which cancers the LGBTQ+ population is at increased risk for and why.
Becker’s Hospital Review – July 13
Benzinga – July 11
Anixa Biosciences Inc ANIX said the European Patent Office has issued an Intention to Grant notice for the first European patent covering its novel CAR-T cancer treatment technology, which has been licensed from The Wistar Institute and is being developed at the Moffitt Cancer Center.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.